Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/medecine/chronic-lymphocytic-leukemia-an-issue-of-hematology-oncology-clinics-of-north-america/descriptif_4554500
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=4554500

0 article 

 Frais de port 0,01€*

Exclusivité web : à partir de 35 euros d’achat, frais de port à 1 centime pour les expéditions vers la France métropolitaine, la Suisse et l’UE avec Colissimo ou GLS

Chronic Lymphocytic Leukemia, An Issue of Hematology/Oncology Clinics of North America The Clinics: Internal Medicine Series

Langue : Anglais

Coordonnateur : Brown? Jennifer R.

Couverture de l’ouvrage Chronic Lymphocytic Leukemia, An Issue of Hematology/Oncology Clinics of North America

This issue of Hematology/Oncology Clinics, guest edited by Dr. Jennifer R. Brown?, will focus on Chronic Lymphocytic Leukemia. This issue is one of six selected each year by our series consulting editors, Dr. George P. Canellos and Dr. Edward J. Benz. Topics discussed in this issue will include: Chronic Lymphocytic Leukemia: Do We Know the Cell of Origin Yet?; Significance of BCR Stereotypy; Prognostic and Predictive Implications of Cytogenetics and Genomics; Role of Epigenetics in Chronic Lymphocytic Leukemia; Genomics of Resistance to Targeted Therapies; First Line Therapy for Chronic Lymphocytic Leukemia; The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia Therapy; BTK Inhibitors; Minimal Residual Disease; Should Undetectable MRD Be the Goal of Chronic Lymphocytic Leukemia Therapy?; Management of Chronic Lymphocytic Leukemia after Progression on BTK Inhibitors; Role of PI3K Inhibitors in Chronic Lymphocytic Leukemia; Can We Restore the Immunodeficiency of Chronic Lymphocytic Leukemia?; and Immune Therapy for Chronic Lymphocytic Leukemia

Potential Relevance of B-cell Maturation Pathways in Defining the Cell(s) of Origin for Chronic Lymphocytic LeukemiaThe Significance of B-cell Receptor Stereotypy in Chronic Lymphocytic Leukemia: Biological and Clinical ImplicationsPrognostic and Predictive Implications of Cytogenetics and GenomicsGenomics of Resistance to Targeted TherapiesFirst-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia: TP53 Disruption, Richter, and BeyondBruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond IbrutinibShould Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase InhibitorsThe Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic LeukemiaCan Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond

Date de parution :

Ouvrage de 240 p.

Disponible chez l'éditeur (délai d'approvisionnement : 14 jours).

107,08 €

Ajouter au panier

Thème de Chronic Lymphocytic Leukemia, An Issue of... :